Compare Atomera Incorporated (ATOM) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atomera Incorporated vs Crispr Therapeutics AG — how do they compare? Atomera Incorporated trades at $6.48 (market cap $241.98M), while Crispr Therapeutics AG trades at $50.76 (market cap $4.99B). The key difference: Crispr Therapeutics AG is far larger — about 20.6× Atomera Incorporated's market cap, and Atomera Incorporated is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| ATOM | CRSP | |
|---|---|---|
Market Cap | $241.98M | $4.99B |
Sector | Technology | Health |
52-Week High | $12.11 | $76.78 |
52-Week Low | $1.99 | $44.34 |
Enterprise Value | $202.19M | $3.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
